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One potential source for studying CKD in claims is the US Medicare program. Medicare provides health insurance for eligible US adults aged 65 years or older, a population with a high prevalence of CKD. Given that over 95% of older US adults have health insurance through Medicare, it provides a large population with high generalizability to the US population of older adults. 7 One prior study evaluated the validity of Medicare claims for identifying individuals with CKD. 8 The study used data on Medicare beneficiaries presenting to a hospital with a myocardial infarction and several claims algorithms to identify CKD patients, yielding test characteristics ranging from 3% to 27% for sensitivity, 93% to 99% for specificity, 89% to 97% for PPV, and 32% to 37% for NPV. Given the high PPV and high specificity, the authors concluded that patients identified in Medicare as having CKD most likely have it, and cohorts of older adults with CKD can be assembled using Medicare claims.
As claims-based algorithms have generally demonstrated low sensitivity, they do not identify the majority of individuals with CKD. Studies using Medicare claims data to identify populations with CKD could produce biased results if the characteristics of individuals with CKD identified through Medicare claims are systematically different from those who are not identified. To better understand the strengths and limitations of using claims data to study CKD, we determined whether (1) correlates of having CKD, (2) the risk for all-cause mortality and end-stage renal disease (ESRD) associated with having CKD, and (3) risk factors for all-cause mortality and ESRD among individuals with CKD were similar when CKD was defined using Medicare claims versus estimated glomerular filtration rate (eGFR) and albuminuria measured in a research study. Additionally, among participants with CKD defined using eGFR and albuminuria, we determined whether (4) the presence of Medicare claims for CKD differed by participant characteristics and co-morbid conditions and (5) the risk for all-cause mortality and ESRD differed for those with versus without CKD claims in Medicare.
METHODS

Study Participants
We conducted an analysis of participants enrolled in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study linked to Medicare claims data. REGARDS is a population-based cohort study of 30,239 adults aged 45 years or older from across the continental United States. 9 Participants were enrolled from January 2003 through October 2007, and baseline data were collected during a telephone interview followed by an in-home study visit.
The REGARDS participants were linked to Medicare enrollment and claims data by social security number, gender, and date of birth. Medicare Part A covers hospital care, skilled nursing facility care, hospice, and home health services. Medicare Part B covers services or supplies that are needed to diagnose or treat medical conditions and preventive services such as to prevent illness or detect it at an early stage. Medicare Advantage plans include health plans offered by private companies that contract with Medicare to provide beneficiaries with coverage. Medicare Advantage plans include health maintenance organizations, preferred provider organizations, private fee-for-service plans, special needs plans, and Medicare medical savings account plans.
For this analysis, we included REGARDS participants who were aged 65 years or older at the beginning of a two-year look-back period (i.e., two years prior to the baseline REGARDS study visit) and provided a blood and urine sample during their in-home REGARDS study visit, had complete data for calculating eGFR and albumin-creatinine ratio (ACR), and had been living in the United States, continuously enrolled in Medicare parts A and B (fee-for-service hospital and outpatient coverage), but not in a Medicare Advantage plan for the two year look-back period.
We excluded participants enrolled in a Medicare Advantage plan as claims are not complete for these individuals. Additionally, we excluded participants who self-reported a history of ESRD at baseline or who had a record for ESRD in the US Renal Data System (USRDS) prior to their REGARDS baseline study visit.
A CONSORT diagram is provided in Figure 1 . Overall, 6,982 participants met all of the inclusion criteria for this analysis. Institutional review boards of the collaborating institutions approved the REGARDS Study protocol and participants gave informed consent.
Determination of CKD in the REGARDS Study (CKD REGARDS )
Serum creatinine assays, calibrated with an isotope dilution mass spectroscopic standard, were performed at the University of Vermont. 10 The CKD-EPI (CKD Epidemiology Collaboration) creatinine equation was used to calculate eGFR. 11 Results were similar using the Modification of Diet in Renal Disease (MDRD) Study equation and therefore not presented. Urinary albumin and creatinine were measured at the Department of Laboratory Medicine and Pathology at the University of Minnesota, using the BN ProSpec Nephelometer from Dade Behring (Marburg, Germany). The results were expressed for each participant as the ACR. For our primary analysis, CKD in the REGARDS study (CKD REGARDS ) was defined as an eGFR < 60 ml/min/1.73 m 2 or an ACR > 30 mg/g. 12 In secondary analyses, we defined CKD REGARDS as an eGFR < 45 ml/min/1.73 m 2 or an ACR > 300 mg/g. This definition of CKD REGARDS was used to capture a cohort of participants with more severe CKD.
Other Variables From the REGARDS Baseline Visit
Self-reported items determined in the REGARDS Study included age, race, gender, region of residence (West, Midwest, Northeast, and South), current smoking, family history of ESRD, history of coronary heart disease (CHD), history of diabetes, and use of antihypertensive, insulin or antidiabetes medications. During the REGARDS baseline study visit, blood pressure and anthropometric variables were measured. Blood pressure was measured two times and averaged for analysis. Hypertension was defined as systolic blood pressure ≥ 140 mm Hg, diastolic blood pressure ≥ 90 mm Hg, or current antihypertensive medication use. Waist circumference was measured mid-way between the lowest rib and the iliac crest using a tape measure with the participant standing; abdominal obesity was defined as levels > 88 cm for women and > 102 cm for men. Using blood collected during the baseline study visit, serum glucose and hemoglobin were measured. Anemia was defined as a hemoglobin level < 12 g/dL for women and < 13 g/dL for men. Diabetes mellitus was defined as fasting glucose level ≥ 126 mg/dL, non-fasting glucose ≥ 200 mg/dL, or selfreport of a prior diagnosis of diabetes mellitus with current use of insulin or antidiabetes medication.
Medicare Claims
Medicare claims for the current analysis include those from the outpatient and inpatient settings. To identify CKD in Medicare claims (CKD Medicare ), we abstracted Medicare claims during the two years prior to each participant's REGARDS study visit (i.e., the lookback period). For the primary analysis, the algorithm for defining CKD Medicare follows that from the Centers for Medicare & Medicaid Services (CMS) chronic conditions warehouse (Item S1, available as online supplementary material). [13] [14] [15] This algorithm uses ICD-9 discharge diagnosis codes associated with a hospitalization or physician evaluation and management claims associated with outpatient physician visits. Coding in Medicare is a two-step process. Physicians provide diagnostic and procedures that were performed and administrative staff translate these into codes for billing purposes. Modifications to ICD-9 codes are used in Medicare claims. Therefore, some of the codes used in the current study may not be present in other settings. In secondary analyses, we evaluated the sensitivity, specificity, PPV and NPV using a more narrow set of claims to define CKD Medicare (Item S2). The claims used in the secondary analyses were chosen by authors to be more specific in identifying individuals with CKD as opposed to acute or transient kidney problems. For each participant, we also identified the number of outpatient visits, hospitalizations, and the occurrence of a nephrologist visit from Medicare claims during the two-year look-back period.
Outcomes
Participants were followed for all-cause mortality and incident ESRD. Mortality, subsequent to the REGARDS Study in-home examination and through March 2012 was assessed through contact with proxies provided by the participant upon recruitment or during followup. If a proxy reported a participant had died, an interview was conducted with their next of kin. The REGARDS Study confirmed dates of death through the Social Security Death Index, death certificates, or the National Death Index. ESRD subsequent to the in-home examination and through September 2011 was assessed via linkage with the USRDS. The USRDS is a registry of ESRD and captures the vast majority of incident cases in the United States. 16 
Statistical Analysis
The sensitivity, specificity, PPV, and NPV of CKD Medicare during the look-back period was calculated, with CKD REGARDS considered the "gold standard". Additionally, sensitivity, specificity, PPV and NPV for CKD Medicare was calculated for level of eGFR (<60, <45, and <30 ml/min/1.73 m 2 and ACR > 30 and >300 mg/g). In a sensitivity analysis, we also calculated these test characteristics for CKD Medicare using Medicare claims from the one year before to one year after each participant's REGARDS Study visit. Participant characteristics were calculated by the cross-classification of CKD Medicare and CKD REGARDS with the statistical significance of differences calculated using ANOVA, a Kruskal-Wallis or chi-square test. Next, hazard ratios for all-cause mortality and ESRD were calculated using Cox proportional hazards models comparing individuals with versus without CKD Medicare and, separately, with versus without CKD REGARDS . Hazard ratios for ESRD were calculated accounting for the competing risk of mortality using the method described by Fine and Gray. 17 Three levels of adjustment were performed. An initial model included adjustment for age, race, and gender. A second model included additional adjustment for number of outpatient visits, nephrologist visits, hospitalization and Medicaid eligibility during the lookback period as identified in Medicare. A third model also adjusted for smoking, abdominal obesity, hypertension, diabetes, and history of CHD from the REGARDS study. To evaluate whether risk factors for outcomes differ for individuals identified as having CKD in claims versus in a research study, we calculated the age, race, sex adjusted hazard ratios for allcause mortality and ESRD among individuals with CKD Medicare (n=451) and, separately, among those with CKD REGARDS (n=2,203).
Next, to evaluate the selective coding of CKD in claims data, we restricted the sample to participants with CKD REGARDS and calculated the proportion of participants with CKD Medicare by demographic factors, co-morbid conditions and Medicare variables. The prevalence ratios for having CKD Medicare associated with participant characteristics were also calculated. Also, among those with the CKD REGARDS , rates and hazard ratios for allcause mortality and, separately, ESRD associated with having versus not having CKD Medicare were calculated. Prevalence ratios and hazard ratios were calculated with three levels of adjustment as described above. Additionally, we calculated the sensitivity, specificity, PPV and NPV for CKD Medicare using the secondary definition of CKD REGARDS (eGFR < 45 ml/min/1.73 m 2 or ACR > 300 mg/g). The rates and hazard ratios for all-cause mortality and ESRD associated with having versus not having CKD Medicare among those with CKD REGARDS were also calculated using this secondary definition. Multiple imputation was conducted using chained equations to account for missing data from the REGARDS Study. Data were missing for <1% of all variables except history of CHD (1.7% missing) and anemia (38.0% missing) and family history of ESRD (35.6% missing). The high percentage of participants missing anemia and family history of ESRD occurred because these variables were added to REGARDS data collection in May 2004 (about one third through recruitment of the cohort). Analyses were conducted using SAS V9.3 (SAS Institute Inc, Cary, NC) and Stata/MP 12.1 (Stata Corp, College Station, TX).
RESULTS
Test Characteristics of CKD Claims in Medicare
Overall, 2,203 of the 6,982 participants (32%) included in this analysis met the primary definition for CKD REGARDS (eGFR < 60 ml/min/1.73 m 2 or ACR > 30 mg/g) and 6% (n=451) met the primary definition for CKD Medicare (NPV) . Sensitivity was higher but specificity and PPV were lower for identifying lower levels of eGFR and higher levels of ACR (Table S1 ). Using Medicare claims from one year before to one year after the REGARDS study visit, the sensitivity, specificity, PPV, and NPV were 21.2% (95% CI, 19.5%-22.9%), 96.9% (95% CI, 96.3%-97.3%), 75.6% (95% CI, 72.1%-79.0%), and 72.7% (95% CI, 71.6%-73.8%), respectively.
Overall, 379 participants met the secondary definition for CKD Medicare (Figure 2 -right  panel) . The sensitivity was lower and the specificity and PPV were higher for this secondary definition. Sensitivity was higher but specificity and PPV were lower using the secondary definition of CKD Medicare to identify lower levels of eGFR and higher levels of ACR (Table  S2) . Due to the lower number of cases of CKD Medicare using this secondary definition, it was not investigated further.
Factors and Outcomes Associated With CKD REGARDS and CKD Medicare
Characteristics of participants by the cross-classification of CKD Medicare and CKD REGARDS is provided in Table 1 . CKD Medicare and CKD REGARDS were each associated with an increased risk for all-cause mortality and ESRD (Table 2) . Although the mortality rate and incidence of ESRD were higher among participants with CKD Medicare compared to their counterparts with CKD REGARDS , the hazard ratio for mortality was similar for CKD Medicare and CKD REGARDS and the hazard ratio for ESRD associated with CKD REGARDS was numerically larger than for CKD Medicare .
Risk Factors for All-Cause Mortality and ESRD Among Participants With CKD Medicare and CKD REGARDS
Among participants with CKD Medicare and those with CKD REGARDS , older age, anemia, ACR > 30 mg/g, and being hospitalized during baseline were associated with an increased risk for all-cause mortality (Table 3) . Among those with CKD REGARDS , women were less likely to die than men but no association between gender and all-cause mortality was present among those with CKD Medicare . Diabetes and history of CHD were associated with an increased risk for all-cause mortality among those with CKD REGARDS but not for those with CKD Medicare while eGFR<60 ml/min/1.73 m 2 was associated with an increased risk for allcause mortality among those with CKD Medicare but not their counterparts with CKD REGARDS . Older age was associated with a lower risk for ESRD among those with CKD Medicare and CKD REGARDS . Being black versus white, having diabetes, anemia, eGFR<60 ml/min/1.73 m 2 , ACR > 30 mg/g, and having a nephrologist visit were each associated with an increased risk for ESRD among those with CKD Medicare and CKD REGARDS . A history of CHD was associated with an increased risk for ESRD among those with CKD REGARDS but not those with CKD Medicare .
Factors and Outcomes Associated With CKD Medicare Among Individuals With CKD REGARDS
Among participants with CKD REGARDS , blacks, non-smokers, individuals with abdominal obesity, hypertension, diabetes, a history of CHD, anemia, eGFR < 60 ml/min/1.73 m 2 , ACR > 30 mg/g were more likely to have CKD Medicare (Table S3) . Additionally, having more outpatient visits, being hospitalized, having a nephrologist visit, and being Medicaid eligible during the look-back period were each associated with having CKD Medicare . After multivariable adjustment, each of these factors except being black, not smoking, hypertension, history of CHD, ACR > 30 mg/g and being Medicaid eligible remained associated with an increased prevalence of CKD Medicare (Table 4) .
Among participants with CKD REGARDS , the crude mortality rate and age, race, gender adjusted hazard ratio for mortality was increased for those with versus without CKD Medicare ( Table 5 ). The hazard ratio was 1.23 (95% CI, 0.99-1.53) after full multivariable adjustment. Among participants with CKD REGARDS , the incidence of ESRD was 4.4 (95% CI, 3.2-5.7) and 22.1 (95% CI, 15.0-29.2) per 1,000 person-years among those without and with CKD Medicare , respectively. The increased risk for ESRD associated with CKD Medicare remained present after multivariable adjustment.
Secondary Definition of CKD REGARDS
Overall, 603 REGARDS participants (9%) had an eGFR < 45 ml/min/1.73 m 2 or ACR > 300 mg/g. Of participants meeting this secondary definition of CKD REGARDS , 32.8% (95% CI, 29.1%-36.7%) had CKD Medicare ( Figure S1 ). In contrast, 96.0% (95% CI, 95.5%-96.5%) of participants not meeting the secondary definition of CKD REGARDS did not have CKD Medicare . Using the secondary definition of CKD REGARDS , the PPV and NPV for CKD Medicare were 43.9% (95% CI, 39.3%-48.6%) and 93.8% (95% CI, 93.2%-94%), respectively. Among participants meeting the secondary definition of CKD REGARDS , the risk for mortality was similar for participants with and without CKD Medicare (Table S4 ). The ESRD risk was higher for those with versus without CKD Medicare . This association was attenuated and no longer present after adjustment for age, race, gender, and Medicare variables from the look-back period.
DISCUSSION
In this study, the majority of individuals with CKD in the REGARDS Study (CKD REGARDS ) as defined by eGFR < 60 ml/min/1.73 m 2 or ACR > 30 mg/g did not have Medicare claims for CKD (CKD Medicare ). This confirms prior studies showing claims data have low sensitivity for identifying CKD. The current study extends findings from prior studies by demonstrating the similarities and differences that exist when defining CKD using eGFR and ACR versus a claims data definition of CKD. With few exceptions, the same factors were associated with CKD REGARDS and CKD Medicare , and CKD REGARDS and CKD Medicare were each associated with an increased risk for all-cause mortality and ESRD. However, some risk factors for all-cause mortality and ESRD differed for individuals with CKD Medicare and CKD REGARDS , and among individuals with CKD REGARDS , we identified differences among individuals with versus without CKD Medicare . For example, among individuals with CKD REGARDS, those with co-morbidities including diabetes, anemia and more severe kidney disease at baseline were more likely to have CKD Medicare . Individuals with CKD Medicare also had very high risk for ESRD.
The validity of Medicare claims to identify individuals with CKD has been evaluated previously. 8 The sensitivity, specificity, PPV and NPV for having CKD associated with Medicare claims was studied in 1,852 low income Medicare beneficiaries presenting to a hospital for myocardial infarction. The eGFR was calculated from the first in-hospital serum creatinine measurement and claims for CKD were identified over the 12 and 24 months prior to hospitalization. The prevalence of CKD was 67% (versus 32% in the present study) and the PPV ranged from 89% to 97% depending on the ICD-9 codes used to define CKD (versus 76% in the present study). Given the high PPV, the authors concluded claims data can be used to identify cohorts with "clinically relevant CKD". However, PPV is influenced by the prevalence of the outcome (e.g., CKD) with higher values present at higher disease prevalences. The lower prevalence of CKD in the REGARDS Study, when compared with prior studies of hospitalized patients, may explain the lower PPV we observed in the current study. A substantially higher sensitivity was present for more severe CKD (e.g., 36% and 56% for identifying eGFR <45 ml/min/1.73 m 2 and < 30 ml/min/1.73 m 2 , respectively). Due to the low prevalence of these more severe reductions in eGFR, the PPV was substantially lower.
The current study extends prior investigations in several important ways. We included a population-based sample rather than patients presenting to the hospital with myocardial infarction and defined CKD using either reduced eGFR or elevated ACR. A number of recent studies and meta-analyses have demonstrated the prognostic importance of albuminuria for cardiovascular and kidney disease outcomes. [18] [19] [20] Additionally, the REGARDS Study had data on a broad range of objectively measured co-morbid conditions that allowed us to assess the generalizability of Medicare beneficiaries with CKD claims. Among those with CKD REGARDS , determined by eGFR and ACR levels measured objectively in the REGARDS study, we found those with versus without CKD Medicare to have more co-morbid conditions including abdominal obesity, diabetes and an eGFR < 60 ml/min/1.73 m 2 .
Traditional epidemiology studies are very expensive and take a long time to conduct. Therefore, claims data may provide an alternative approach to study CKD. In the current study, we found correlates of CKD and the risk for all-cause mortality to be similar when CKD was defined in claims data or in the REGARDS Study. However, the incidence of ESRD was substantially higher among individuals with CKD Medicare versus CKD REGARDS . Additionally, in the current analysis, four risk factors (gender, diabetes, history of CHD and eGFR < 60 ml/min/1.73 m 2 ) for all-cause mortality and one risk factor (history of CHD) for ESRD were different when evaluated in two parallel cohorts of individuals with CKD, one defined using claims data and the other by measured eGFR and ACR. This suggests that assembling a cohort of individuals with CKD claims to study risk factors for outcomes may lead to different findings compared to studies that use measured eGFR and ACR to define CKD.
Although the current study found potential limitations in using claims data to study CKD in Medicare, algorithms for identifying several other diseases including diabetes, heart failure, and myocardial infarction have been validated in claims databases. [21] [22] [23] In general, these algorithms had substantially higher PPV than observed for CKD in the current study. For our primary analysis we used a broad set of claims to identify CKD. The narrower set of ICD-9 codes we used to define CKD in Medicare in secondary analyses resulted in a higher PPV but the sensitivity remained low. Future studies are needed to investigate whether other algorithms with higher sensitivity and PPV can be developed to identify CKD in Medicare claims.
The current study should be interpreted in the context of potential and known limitations. While the REGARDS Study measured both eGFR and ACR, they were obtained at a single time point. Some REGARDS participants identified as having CKD may not have had it if repeat eGFR or ACR measurements were performed. 24 The baseline visit in the REGARDS Study occurred in [2003] [2004] [2005] [2006] [2007] . ICD-9 diagnosis codes corresponding to CKD stage were introduced into Medicare claims in 2005. Too little look-back time was available in the current study to investigate the correlation of 585 sub-codes with CKD stage. Also, future studies with more contemporary data on CKD are needed to re-evaluate whether the differences between individuals with and without CKD claims in Medicare still remain present. Strengths of the current analysis include the large nationwide reach of the REGARDS Study. Participants were enrolled from across the continental United States. Broad data collection was conducted at baseline using a standardized protocol and participants have been prospectively followed for outcomes. This allowed us to evaluate correlates and outcomes associated with having CKD claims.
In conclusion, the current analysis identified similarities and differences between older US adults with CKD identified in a research study versus in Medicare claims. Our data suggest that most individuals with claims for CKD in Medicare have reduced eGFR or albuminuria. Additionally, CKD, whether identified using a claims-based algorithm or through eGFR and ACR measurements, is associated with an increased risk for all-cause mortality and ESRD. However, regardless of the algorithm applied in the current study, Medicare claims algorithms had low sensitivity and identified a subset of individuals with CKD who had a high mortality and ESRD risk. Future studies are needed to assess whether the generalizability of individuals identified as having CKD in Medicare claims has improved since 2007 and to develop better approaches for identifying CKD in claims. In the interim, the inferences from studies of CKD defined using Medicare claims should be interpreted with caution.
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